Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) and Revolution Medicines (NASDAQ:RVMD – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.
Valuation and Earnings
This table compares Kiniksa Pharmaceuticals International and Revolution Medicines”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kiniksa Pharmaceuticals International | $677.56 million | 9.25 | $59.01 million | $0.97 | 82.85 |
| Revolution Medicines | $11.58 million | 3,956.87 | -$1.13 billion | ($8.82) | -24.24 |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Kiniksa Pharmaceuticals International and Revolution Medicines, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kiniksa Pharmaceuticals International | 0 | 2 | 8 | 0 | 2.80 |
| Revolution Medicines | 1 | 1 | 18 | 1 | 2.90 |
Kiniksa Pharmaceuticals International presently has a consensus target price of $87.38, suggesting a potential upside of 8.72%. Revolution Medicines has a consensus target price of $166.33, suggesting a potential downside of 22.19%. Given Kiniksa Pharmaceuticals International’s higher possible upside, equities analysts plainly believe Kiniksa Pharmaceuticals International is more favorable than Revolution Medicines.
Profitability
This table compares Kiniksa Pharmaceuticals International and Revolution Medicines’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kiniksa Pharmaceuticals International | 9.59% | 13.65% | 10.09% |
| Revolution Medicines | N/A | -88.20% | -57.85% |
Risk and Volatility
Kiniksa Pharmaceuticals International has a beta of 0.05, suggesting that its stock price is 95% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.
Insider & Institutional Ownership
53.9% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Kiniksa Pharmaceuticals International beats Revolution Medicines on 9 of the 15 factors compared between the two stocks.
About Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
About Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company’s RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Receive News & Ratings for Kiniksa Pharmaceuticals International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals International and related companies with MarketBeat.com's FREE daily email newsletter.
